2026 Bulk Price Outlook for Methyl 1-(Mercaptomethyl)cyclopropaneacetate (CAS 152922-73-1)

• Projected 2026 bulk prices reflect tightening supply chains and rising demand for high-purity Montelukast intermediates.
• Industrial purity (>98%) and robust COA documentation are now baseline requirements for API-grade procurement.
• Efficient synthesis routes and vertical integration significantly impact FOB/CIF pricing competitiveness in global markets.

As the pharmaceutical industry intensifies its focus on leukotriene receptor antagonists like Montelukast, the demand for high-purity Methyl 1-(Mercaptomethyl)cyclopropaneacetate (CAS 152922-73-1) continues to grow. This key intermediate—also referred to as methyl 2-(1-(mercaptomethyl)cyclopropyl)acetate or 2-[1-(mercaptomethyl)cyclopropyl]acetic acid methyl ester—is essential in constructing the thioether side chain of Montelukast. With 2026 approaching, bulk buyers are increasingly concerned with both cost efficiency and supply reliability, especially amid fluctuating raw material costs and regulatory scrutiny.

Global Bulk Pricing Trends for CAS 152922-73-1 in 2026

Historical data indicates that small-scale laboratory pricing (e.g., $45 for 500 mg in 2021) is not representative of industrial bulk economics. In contrast, commercial-scale procurement—typically starting at 1 kg and scaling to multi-ton batches—operates under a fundamentally different pricing model driven by synthesis efficiency, yield optimization, and economies of scale.

For 2026, industry analysts project moderate upward pressure on bulk prices due to:

• Increased demand from generic Montelukast producers in emerging markets
• Stricter environmental regulations affecting thiol-based synthesis routes
• Rising costs of cyclopropanation reagents and chiral resolution agents

However, manufacturers with vertically integrated processes and optimized reaction pathways can mitigate these pressures. Notably, NINGBO INNO PHARMCHEM CO.,LTD. has demonstrated consistent capacity to deliver Methyl 1-(Mercaptomethyl)cyclopropaneacetate at competitive bulk rates while maintaining >98.5% industrial purity—a benchmark now expected by major API developers.

Factors Influencing FOB and CIF Pricing for Pharmaceutical Intermediates

The final landed cost of methyl 2-[1-(mercaptomethyl)cyclopropyl]acetate depends on multiple commercial and technical variables beyond base chemical price:

Factor	Impact on Price
Synthesis Route Efficiency	Shorter routes with higher yields (e.g., direct mercaptomethylation vs. multi-step protection/deprotection) reduce COGS by 15–25%.
Purity & Impurity Profile	Pharma-grade batches require ≤0.1% total impurities; tighter specs increase analytical and purification costs.
COA & Regulatory Documentation	Full GMP-compliant COA, including residual solvent and heavy metal reports, is non-negotiable for API use.
Shipping Terms (FOB vs. CIF)	CIF pricing includes freight and insurance but offers less control; FOB allows buyers to optimize logistics independently.

When sourcing high-purity Methyl 1-(Mercaptomethyl)cyclopropaneacetate, buyers should prioritize suppliers with auditable manufacturing processes and batch-specific COAs—not just the lowest headline price.

How to Source High-Purity Methyl 1-(Mercaptomethyl)cyclopropaneacetate at Scale

Procuring this intermediate in bulk requires a strategic approach centered on technical validation and supply chain resilience. The compound’s molecular formula (C₇H₁₂O₂S, MW: 160.23) and reactive thiol group necessitate careful handling to prevent oxidation or dimerization during storage and transit.

Leading global manufacturers like NINGBO INNO PHARMCHEM CO.,LTD. address these challenges through:

• Dedicated thiol-handling infrastructure with nitrogen-blanketed reactors and cold-chain logistics
• In-house QC labs capable of NMR, GC-MS, and chiral HPLC for full impurity profiling
• Scalable synthesis routes achieving >85% isolated yield with minimal chromatographic purification

Furthermore, their production of 1-(mercaptomethyl)cyclopropaneacetic acid methyl ester adheres to ICH Q11 guidelines, ensuring consistency across batches—an essential requirement for regulatory filings.

For bulk inquiries in 2026, prospective buyers should request:

1. Detailed COA with assay, related substances, residual solvents, and water content
2. Stability data under ICH conditions (25°C/60% RH and 40°C/75% RH)
3. Scalability confirmation (e.g., successful multi-hundred-kilogram campaigns)

Given its role as a critical Montelukast building block, securing a reliable source of methyl 2-(1-(mercaptomethyl)cyclopropyl)acetate well ahead of formulation timelines is strongly advised. With NINGBO INNO PHARMCHEM CO.,LTD.’s established track record in complex sulfur-containing intermediates, they remain a premier choice for cost-effective, high-integrity supply into 2026 and beyond.